Assessment of the Cardiovascular Risk of Olmesartan Medoxomil-Based Treatment: Meta-Analysis of Individual Patient Data
DiscussionThe results from this meta-analysis did not show a clinically meaningful or statistically significant difference in cardiovascular risk between OM and the placebo/active control groups, and thus did not corroborate the numerical imbalance observed in ROADMAP and ORIENT.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Benicar | Cardiology | Cardiovascular | Clinical Trials | Databases & Libraries | Heart | Statistics | Study